In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
Status:
Not yet recruiting
Trial end date:
2032-01-01
Target enrollment:
Participant gender:
Summary
This study is investigating a new technique for delivering chemotherapy directly into the
lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially
kill any microscopic cancer cells that are present in the lungs at the time of surgery, while
sparing other major organs in the body from the side effects of chemotherapy. This technique
is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP
technique has been used recently in a Phase I study in patients with sarcoma, and we are now
expanding on that experience to include patients with colorectal metastases. The purpose of
this study is to test the safety of the IVLP technique and find the dose that seems right in
humans. Participants are given oxaliplatin into one lung via IVLP and are watched very
closely to see what side effects they have and to make sure the side effects are not severe.
If the side effects are not severe, then more participants are asked to join the study and
are given a higher dose of oxaliplatin. Participants joining the study later on will get
higher doses of oxaliplatin than participants who join earlier. This will continue until a
dose is found that causes severe but temporary side effects. Doses higher than that will not
be given. The other lung will not be infused with anything, so that we can limit unforeseen
toxicity to a single lung and see if one lung does better than the other.